Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
:TGTX
Holding TGTX?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.16Last Year’s EPS
-0.09Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 09, 2018
|% Change Since: 8.33%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive sentiment, driven by robust sales growth, promising clinical data, and strategic investments into expanding the commercial infrastructure and product pipeline. While there are slight market challenges and competitive considerations, the outlook remains highly optimistic.Company Guidance
During the TGTX earnings call for Q3 2024, the executives provided optimistic revenue guidance for the year, raising their full-year U.S. net sales forecast for BRIUMVI to $300 million to $305 million, up from their original guidance of $220 million to $260 million. This revision comes on the heels of $83.3 million in net sales for the third quarter, marking a 15% quarter-over-quarter growth and over 230% growth from the same quarter last year. The company aims to continue this positive momentum into 2025, supported by expanding their commercial infrastructure and patient awareness efforts. Additionally, they are exploring enhancements like faster infusion times and new delivery methods for BRIUMVI, while maintaining a strong focus on research and development, including a potential pivotal trial for a subcutaneous version and a Phase I study for their off-the-shelf CAR T cell therapy.Strong BRIUMVI Sales Growth
BRIUMVI third quarter U.S. net sales were $83.3 million, reflecting approximately 15% quarter-over-quarter growth and over 230% growth from the same quarter last year.
Positive Clinical Data for BRIUMVI
Positive data from the ULTIMATE I and II trials and the ENHANCE Phase IIIb trial presented at the ECTRIMS meeting, showing 92% of patients were free from disability progression after 5 years. The annualized relapse rate of 0.02 was observed.
Improved Commercial Operations
Expansion of commercial infrastructure, doubling the team size and increasing presence in key markets, leading to 95% coverage with national and regional payers.
Financial Performance
Generated net income of approximately $3.9 million for the 3 months ended September 2024, with a strong cash position of approximately $341 million.
Future Growth Initiatives
Development of subcutaneous BRIUMVI and commencement of Phase I study for azer-cel, an off-the-shelf allogeneic CD19 CAR T cell therapy for the treatment of autoimmune diseases.
---
TGTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TGTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $26.90 | $24.36 | -9.44% |
| Aug 06, 2024 | $17.21 | $20.58 | +19.58% |
| May 01, 2024 | $13.66 | $15.88 | +16.25% |
| Feb 28, 2024 | $13.91 | $17.63 | +26.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does TG Therapeutics (TGTX) report earnings?
TG Therapeutics (TGTX) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is TG Therapeutics (TGTX) earnings time?
TG Therapeutics (TGTX) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TGTX EPS forecast?
TGTX EPS forecast for the fiscal quarter 2024 (Q4) is 0.16.
---